• About
  • Advertise
  • Careers
  • Contact
  • Cookie Policy (EU)
Wednesday, February 1, 2023
  • Login
No Result
View All Result
NEWSLETTER
Tipperary Times - Tipperary News as it Happens
  • Local News
  • Community
  • Business
  • Farming
  • Politics
  • Education
  • Life Style
  • Jobs
  • Sport
  • Local News
  • Community
  • Business
  • Farming
  • Politics
  • Education
  • Life Style
  • Jobs
  • Sport
No Result
View All Result
Tipperary Times - Tipperary News as it Happens
No Result
View All Result
Home Business

NUTRIBAND INC. SIGNS LOI TO ACQUIRE CARMEL BIOSCIENCES

by Paddy Ryan
June 13, 2018
in Business
0
Gareth Sheridan Nutriband

Gareth Sheridan Nutriband

0
SHARES
Share on FacebookShare on Twitter
US based Pharmaceutical company continues to grow under Irish Entrepreneurs stewardship
Nutriband Inc. has today announced that it has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies. Nutriband plans to complete the deal, valued at approximately $3.8 million, through payment of 450,000 restricted common shares of the Company’s stock.
This is the latest in a series of moves from Nutriband Inc. and their Irish CEO, Gareth Sheridan. Sheridan, originally from Terenure and a former winner of the BOI Best Young Entrepreneur in the 2014 BOI Startup awards, has seen Nutriband make a series of acquisitions in recent months aimed at consolidating their position in the transdermal and novel drug delivery space.
The company, now valued at over $185M dollars has had a busy 12 months including the previous acquisition of 4P Therapeutics in April this year and in February the company added seasoned businessman Sean Gallagher to the management and BOD
“The Carmel Biosciences team combines a deep understanding of lipid biochemistry and clinical expertise in the cardiovascular and metabolic space,” stated Gareth Sheridan, CEO of Nutriband. “Carmel’s focus in the reformulation of drugs with a high degree of safety and efficacy allows improved access to patients who have difficulty swallowing tablets or capsules and provides enhanced usage of these widely acclaimed products”.
In December 2017, Carmel Biosciences received FDA approval for PREXXARTAN™, the first and only approved oral liquid dosage form of the angiotensin receptor blocker (ARB) valsartan in the United States.
PREXXARTAN™ (valsartan oral solution) is indicated for treatment of hypertension in adults and children six years and older. PREXXARTAN™ is also indicated for use as therapy for the treatment of heart failure (NYHA class II-IV). Additionally, PREXXARTAN™ has also been indicated for stable left ventricular failure or left ventricular dysfunction after myocardial infarction.
The hypertension therapeutics market is growing at a compound annual growth rate of 3.2% and is expected to reach $4.75 billion by 2024, according to research and consulting firm GlobalData.
Read more about Nutriband on https://nutriband.com
Tags: nutribandpatchestransdermal health
Next Post

Upperchurch Drombane GAA Clubnews - Weekly Club Notes – June 14th 2018

© 2021 An AMV Publication - Agency Partner Trigger Media.

No Result
View All Result
  • Home
  • Community
  • Local News
  • Business
  • Tipperary Sport
  • Farming
  • Obituaries
  • Education
  • Entertainment
  • Health
  • Life Style
  • Opinion
  • Politics
  • Contact

© 2021 An AMV Publication - Agency Partner Trigger Media.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Preferences
{title} {title} {title}